Get started
Author

Veronica Gibaja

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
2017 · E. Robert McDonald, Antoine de Weck, et al. · Cell · 660
PDF
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia
2013 · Jacob D Jaffe, Yan Wang, et al. · Nature Genetics · 284
Class III Phosphatidylinositol 4-Kinase Alpha and Beta Are Novel Host Factor Regulators of Hepatitis C Virus Replication
2009 · Jason Borawski, Philip Troke, et al. · Journal of Virology · 211
Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
2015 · V Gibaja, F Shen, et al. · Oncogene · 151
PDF
A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes
2015 · Qianhe Zhou, Adnan Derti, et al. · Cancer Research · 85
Broad‐spectrum virus reduction in red cell concentrates using INACTINE™ PEN110 chemistry
2002 · A. Lazo, J. Tassello, et al. · Vox Sanguinis · 40
Inactivation of HIV in blood
2002 · Asa Ohagen, Veronica Gibaja, et al. · Transfusion · 25
Optical Mapping of BAC Clones from the Human Y Chromosome DAZ Locus
2000 · Joseph Giacalone, Stephanie Delobette, et al. · Genome Research · 18
PDF
Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110
2004 · A. Ohagen, V. Gibaja, et al. · Vox Sanguinis · 15
Development of models and detection methods for different forms of cytomegalovirus for the evaluation of viral inactivation agents
2006 · Vasudevacharya Jayarama, Jennifer Marcello, et al. · Transfusion · 14
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
2024 · Lily L. Nguyen, Zachary L. Watson, et al. · Molecular Cancer Therapeutics · 12
PDF
EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
2024 · Lily L. Nguyen, Zachary L. Watson, et al. · Molecular Cancer Research · 9
PDF
Duplexed, bead‐based competitive assay for inhibitors of protein kinases
2007 · Peter C. Simons, Susan M. Young, et al. · Cytometry Part A · 9
PDF
Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma
2026 · Elena Adan-Villaescusa, Borja Castello-Uribe, et al. · Cell Reports Medicine · 6
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer
2024 · Robinson Triboulet, Khikmet Sadykov, et al. · Molecular Cancer Therapeutics · 4
Abstract 1161: EZH2 inhibitor tazemetostat demonstrates activity in preclinical models of Bruton's tyrosine kinase inhibitor-resistant relapsed/refractory mantle cell lymphoma
2021 · Jeffrey A. Keats, Arleide Lee, et al. · Cancer Research · 4
Reawakening of Human Fetal Hemoglobin and an Epigenetic Path to the Clinic for Sickle Cell Disease and Beta-Thalassemia: Identification of an Orally-Available, Potent, and Selective Euchromatic Histone Lysine Methyltransferase 1 and 2 (EHMT1/2) Inhibitor
2017 · Elayne Chan-Penebre, Veronica Gibaja, et al. · Blood · 4
Data from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
2024 · Lily L. Nguyen, Zachary L. Watson, et al. · 2
Supplementary Table S1 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
2024 · Lily L. Nguyen, Zachary L. Watson, et al. · 2
Supplementary Table 6 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
2024 · Lily L. Nguyen, Zachary L. Watson, et al. · 1
Supplementary Figure S1 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
2024 · Lily L. Nguyen, Zachary L. Watson, et al. · 1
Supplementary Legends from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
2024 · Lily L. Nguyen, Zachary L. Watson, et al. · 1
Antitumoral activity of the G9a inhibitor EZM8266 in hepatocellular carcinoma: potential for combination with immune checkpoint inhibitors
2023 · Maite G Fernandez-Barrena, José María Herranz, et al. · Journal of Hepatology · 1
Supplementary Table 7 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
2026 · Lily L. Nguyen, Zachary L. Watson, et al.
Supplementary Figure S3 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
2026 · Lily L. Nguyen, Zachary L. Watson, et al.
Works count: 102
Citation count: 1,559
H-index: 11
I10-index: 11
Year
Topic
Type